97 related articles for article (PubMed ID: 19092279)
1. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
Ueshima K; Kudo M; Nagai T; Tatsumi C; Ueda T; Takahashi S; Hatanaka K; Kitai S; Ishikawa E; Inoue T; Hagiwara S; Minami Y; Chung H
Oncology; 2008; 75 Suppl 1():106-13. PubMed ID: 19092279
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
Nakamura M; Nagano H; Marubashi S; Miyamoto A; Takeda Y; Kobayashi S; Wada H; Noda T; Dono K; Umeshita K; Monden M
Cancer; 2008 Apr; 112(8):1765-71. PubMed ID: 18327806
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases.
Uka K; Aikata H; Mori N; Takaki S; Kawakami Y; Azakami T; Kawaoka T; Jeong SC; Takahashi S; Chayama K
Oncology; 2008; 75(1-2):8-16. PubMed ID: 18719349
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
Cancer; 2012 Jul; 118(13):3302-10. PubMed ID: 22072099
[TBL] [Abstract][Full Text] [Related]
5. [A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN].
Tanisaka Y; Seike H; Matsumoto T; Tanaka Y; Tsubouchi E; Miyauchi S; Iwakawa K; Ichikawa M
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1761-3. PubMed ID: 19838044
[TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
Okita K; Yamasaki T; Hamabe S; Saeki I; Harima Y; Terai S; Sakaida I
Hepatogastroenterology; 2012; 59(114):533-7. PubMed ID: 22353519
[TBL] [Abstract][Full Text] [Related]
7. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
Hagiwara S; Kudo M; Ueshima K; Chung H; Yamaguchi M; Takita M; Haji S; Kimura M; Arao T; Nishio K; Park AM; Munakata H
J Gastroenterol; 2011 Feb; 46(2):212-21. PubMed ID: 20683621
[TBL] [Abstract][Full Text] [Related]
8. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Katamura Y; Aikata H; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Ishikawa M; Hieda M; Kakizawa H; Chayama K
J Gastroenterol Hepatol; 2010 Jun; 25(6):1117-22. PubMed ID: 20074168
[TBL] [Abstract][Full Text] [Related]
9. A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
Nakamura M; Nagano H; Wada H; Noda T; Ota H; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
J Gastroenterol; 2006 Nov; 41(11):1120-5. PubMed ID: 17160524
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
Int J Clin Oncol; 2011 Jun; 16(3):221-9. PubMed ID: 21132451
[TBL] [Abstract][Full Text] [Related]
11. [S-1 treatment against advanced HCC].
Nakamura M; Nagano H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():230-5. PubMed ID: 16898008
[TBL] [Abstract][Full Text] [Related]
12. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases.
Katamura Y; Aikata H; Hashimoto Y; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Chayama K
Hepatogastroenterology; 2010; 57(102-103):1272-8. PubMed ID: 21410071
[TBL] [Abstract][Full Text] [Related]
14. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.
Kurokohchi K; Takaguchi K; Kita K; Masaki T; Kuriyama S
World J Gastroenterol; 2005 Sep; 11(34):5401-3. PubMed ID: 16149157
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
Mawatari H; Kirikoshi H; Yoneda M; Higurashi T; Fujita K; Saito S; Inamori M; Takahashi H; Abe Y; Kubota K; Nakajima A
Hepatogastroenterology; 2008; 55(86-87):1776-7. PubMed ID: 19102391
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
19. [A case of HCC with inferior caval vein tumor thrombus and multiple pulmonary metastases that remarkably responded to combination therapy of TS-1 and interferon-alpha].
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Yoshioka S; Kato H; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1824-8. PubMed ID: 16315953
[TBL] [Abstract][Full Text] [Related]
20. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
